Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Onartuzumab PK and Safety in Chinese Patients with Solid Tumors
NCT02031731Phase 1Completed
- Sponsor
- Roche
- Start
- Jan 2014
- Primary completion
- Apr 2014
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of onartuzumab in solid tumor (3 arms), sponsored by Roche. Primary endpoints: Incidence of adverse events at 1 year and Total exposure of MetMAb (AUC) at 1 year. Started Jan 2014; status: completed.
02
Drugs
onartuzumab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02031731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02031731.